Biocartis

Biocartis Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary Idylla™ Platform.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.*

Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Further information can be found at: www.biocartis.com

* http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market

05/11/2025

📢 𝗡𝗢𝗪 𝗔𝗩𝗔𝗜𝗟𝗔𝗕𝗟𝗘: 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗖𝗗𝘅 𝗠𝗦𝗜 𝗧𝗲𝘀𝘁
For the identification of MSI-H CRC patients who may benefit from treatment with 𝗢𝗣𝗗𝗜𝗩𝗢® (nivolumab) ± 𝗬𝗘𝗥𝗩𝗢𝗬® (ipilimumab)
✔️ 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗼𝗻 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰 for standardized MSI-H and MSS detection in CRC
✔️ Sample to result in approximately 𝟭𝟱𝟬 𝗺𝗶𝗻𝘂𝘁𝗲𝘀 without the need for sample batching
✔️ Concordance rate of 𝟵𝟴.𝟱𝟳% against OncoMate™ MSI Dx Analysis System
✔️ Directly from 𝗙𝗙𝗣𝗘 𝘁𝗶𝘀𝘀𝘂𝗲, no paired tissue samples needed

👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://www.biocartis.com/en-US/meet-idylla/idylla-oncology-assays/idylla-cdx-msi-test



Approved in the US under P250005. OPDIVO® and YERVOY® are registered trademarks of Bristol Myers Squibb Company.

November is Lung Cancer Awareness Month 🤍🫁 💡 Did you know that lung cancer is the most common type of cancer and the l...
03/11/2025

November is Lung Cancer Awareness Month 🤍🫁

💡 Did you know that lung cancer is the most common type of cancer and the leading cause of cancer deaths worldwide? Since lung cancer can progress rapidly, early detection and prompt treatment are crucial for patients ⏳
Idylla™ allows for fast & accurate results of key NSCLC gene mutations and fusions in ⏱️ONLY 3 HOURS⏱️, speeding up therapy decisions for better patient outcomes.

Learn more 👀 https://www.biocartis.com/en/idylla-for-lung-cancer?utm_source=facebook&utm_medium=social&utm_campaign=0311_idylla-for-lung-cancer

29/10/2025

💡 Early detection and prompt treatment are crucial for lung cancer patients
Test for EGFR, ALK, ROS1, RET and METex14 in ONLY 3 HOURS and immediately start the right targeted therapy for >90% of your patients with first-line actionable biomarkers*.

IDYLLA™ FIRST. Guiding First-Line Therapy Decisions in NSCLC ⏱️

Learn more 👉🏻https://www.biocartis.com/sites/default/files/2025-06/idylla_first-line_lung_1l_-_leaflet_-_may2025.pdf


*Hendriks, L. E., et al. (2023). Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 34(4), 339–357.

28/10/2025

𝗡𝗲𝘅𝘁 𝘄𝗲𝗲𝗸 𝘄𝗲 𝗮𝗿𝗲 𝗮𝘁𝘁𝗲𝗻𝗱𝗶𝗻𝗴 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 & 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝟮𝟬𝟮𝟱 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲!
📅 5-6 November | 🗺️ New York, NY, US

Stop by and learn more about getting molecular biomarker results in ⏱️only 3 hours⏱️ with Idylla™!
👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://lnkd.in/eRxYe3YF
👉 𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲: https://lnkd.in/eRx8fbYs

27/10/2025

𝗠𝗮𝗿𝗸 𝘆𝗼𝘂𝗿 𝗰𝗮𝗹𝗲𝗻𝗱𝗮𝗿𝘀 𝗳𝗼𝗿 𝗔𝗠𝗣!
🗓️ 11-15 November |📍Boston, MA, US

Visit us at 𝗯𝗼𝗼𝘁𝗵 𝟰𝟮𝟭 and discover how Idylla™ can deliver your fully automated molecular biomarker results in 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀!
👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://www.biocartis.com/en-US/news-events/events/amp
👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗜𝗱𝘆𝗹𝗹𝗮™: https://www.biocartis.com/en-US/meet-idylla

𝗗𝗼𝗻'𝘁 𝗺𝗶𝘀𝘀 𝗼𝘂𝗿 𝗔𝗠𝗣 𝘄𝗼𝗿𝗸𝘀𝗵𝗼𝗽: 𝘍𝘢𝘴𝘵 𝘌𝘎𝘍𝘙 𝘛𝘦𝘴𝘵𝘪𝘯𝘨 𝘪𝘯 𝘊𝘺𝘵𝘰𝘱𝘢𝘵𝘩𝘰𝘭𝘰𝘨𝘺: 𝘈 𝘗𝘳𝘢𝘤𝘵𝘪𝘤𝘢𝘭 𝘐𝘮𝘱𝘭𝘦𝘮𝘦𝘯𝘵𝘢𝘵𝘪𝘰𝘯 𝘌𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦, hosted by Dr. Roberto Ruiz-Cordero (University of Miami).
🗓️ 12 November, 03:00 PM (EST) | 📍 156AB, level 1

We can’t wait to connect with you in Boston! 👋

24/10/2025

🎗️ This Breast Cancer Awareness Month, we’re turning the spotlight on our Breast Cancer Assay Portfolio

🔬 Our portfolio includes:
- Idylla™ PIK3CA-AKT1 Mutation Assay* - coming soon
- APIS PIK3CA qPCR Kit**
- APIS ESR1 qPCR Kit**
- APIS ESR1 dPCR Kit**
- APIS Breast Cancer Subtyping Kit**
👉 Learn more here: https://www.biocartis.com/en/breast-cancer-assay-portfolio?utm_source=facebook&utm_medium=social&utm_campaign=breast-cancer-assay-portfolio

*For Research Use Only (RUO), not for use in diagnostic procedures.
**Developed by APIS and distributed by Biocartis, for Research Use Only (RUO), not for use in diagnostic procedures. Data and conclusions have not been validated by Biocartis.


Assay Technologies Ltd.

𝗝𝗢𝗜𝗡 𝗢𝗨𝗥 𝗙𝗥𝗘𝗘 𝗪𝗘𝗕𝗜𝗡𝗔𝗥: 𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝗣𝗢𝗟𝗘 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗶𝗻 𝗘𝗻𝗱𝗼𝗺𝗲𝘁𝗿𝗶𝗮𝗹 𝗖𝗮𝗻𝗰𝗲𝗿: 𝗚𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲-𝗕𝗮𝘀𝗲𝗱 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗖𝗹𝗮𝘀𝘀𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻📅 Wednesday...
23/10/2025

𝗝𝗢𝗜𝗡 𝗢𝗨𝗥 𝗙𝗥𝗘𝗘 𝗪𝗘𝗕𝗜𝗡𝗔𝗥: 𝗨𝗻𝗹𝗼𝗰𝗸𝗶𝗻𝗴 𝗣𝗢𝗟𝗘 𝗧𝗲𝘀𝘁𝗶𝗻𝗴 𝗶𝗻 𝗘𝗻𝗱𝗼𝗺𝗲𝘁𝗿𝗶𝗮𝗹 𝗖𝗮𝗻𝗰𝗲𝗿: 𝗚𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲-𝗕𝗮𝘀𝗲𝗱 𝗠𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗖𝗹𝗮𝘀𝘀𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻
📅 Wednesday 29 October, 3:00 PM (CET)
🗣️ Italian
🎤 Dr. Elisa Melucci (IFO – Istituto Regina Elena, Rome)*
📍 Online, registration required

𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀:
• Molecular classification of endometrial carcinoma based on the latest international guidelines
• The Idylla™ POLE-POLD1 Mutation Assay and its fully automated workflow
• Molecular workflow in practice: insights from Dr. Elisa Melucci (IFO – Istituto Regina Elena, Roma)
• Live Q&A session

👉 𝗦𝗮𝘃𝗲 𝘆𝗼𝘂𝗿 𝘀𝗽𝗼𝘁 𝗻𝗼𝘄: https://lnkd.in/eHPJA4me
Can’t join live? By registering, you will get access to the recording afterwards.

𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘗𝘖𝘓𝘌-𝘗𝘖𝘓𝘋1 𝘔𝘶𝘵𝘢𝘵𝘪𝘰𝘯 𝘈𝘴𝘴𝘢𝘺 𝘪𝘴 𝘍𝘰𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘜𝘴𝘦 𝘖𝘯𝘭𝘺 (𝘙𝘜𝘖), 𝘯𝘰𝘵 𝘧𝘰𝘳 𝘶𝘴𝘦 𝘪𝘯 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘱𝘳𝘰𝘤𝘦𝘥𝘶𝘳𝘦𝘴.
*𝘗𝘢𝘳𝘵𝘪𝘤𝘪𝘱𝘢𝘵𝘪𝘰𝘯 𝘴𝘶𝘱𝘱𝘰𝘳𝘵𝘦𝘥 𝘣𝘺 𝘉𝘪𝘰𝘤𝘢𝘳𝘵𝘪𝘴.
___________________________________________
𝗣𝗔𝗥𝗧𝗘𝗖𝗜𝗣𝗔 𝗖𝗢𝗡 𝗡𝗢𝗜 𝗔𝗟 𝗪𝗘𝗕𝗜𝗡𝗔𝗥 𝗚𝗥𝗔𝗧𝗨𝗜𝗧𝗢: 𝗜𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘇𝗶𝗼𝗻𝗲 𝗱𝗲𝗹 𝘁𝗲𝘀𝘁 𝗣𝗢𝗟𝗘 𝗻𝗲𝗹 𝗰𝗮𝗿𝗰𝗶𝗻𝗼𝗺𝗮 𝗲𝗻𝗱𝗼𝗺𝗲𝘁𝗿𝗶𝗮𝗹𝗲: 𝗰𝗹𝗮𝘀𝘀𝗶𝗳𝗶𝗰𝗮𝘇𝗶𝗼𝗻𝗲 𝗺𝗼𝗹𝗲𝗰𝗼𝗹𝗮𝗿𝗲 𝗯𝗮𝘀𝗮𝘁𝗮 𝘀𝘂𝗹𝗹𝗲 𝗹𝗶𝗻𝗲𝗲 𝗴𝘂𝗶𝗱𝗮
📅 Mercoledì 29 ottobre 2025, 15:00 (CET)
🗣️ Italiano
🎤 Dott.ssa Elisa Melucci (IFO - Istituto Regina Elena, Roma)*
📍 On-line, registrazione obbligatoria

𝗔𝗿𝗴𝗼𝗺𝗲𝗻𝘁𝗶 𝗽𝗿𝗶𝗻𝗰𝗶𝗽𝗮𝗹𝗶:
• Classificazione molecolare del carcinoma endometriale secondo le più recenti linee guida internazionali
• Idylla™ POLE-POLD1 Mutation Assay e il suo workflow completamente automatizzato
• Workflow molecolare in pratica: approfondimenti dalla Dott.ssa Elisa Melucci
• Sessione di Q&A in diretta

👉 𝗣𝗿𝗲𝗻𝗼𝘁𝗮 𝗶𝗹 𝘁𝘂𝗼 𝗽𝗼𝘀𝘁𝗼 𝗮𝗱𝗲𝘀𝘀𝗼: https://lnkd.in/eHPJA4me
Non puoi partecipare in diretta? Registrandoti, potrai accedere alla registrazione in seguito.

𝘐𝘥𝘺𝘭𝘭𝘢™ 𝘗𝘖𝘓𝘌-𝘗𝘖𝘓𝘋1 𝘔𝘶𝘵𝘢𝘵𝘪𝘰𝘯 𝘈𝘴𝘴𝘢𝘺 𝘦 𝘥𝘦𝘴𝘵𝘪𝘯𝘢𝘵𝘰 𝘦𝘴𝘤𝘭𝘶𝘴𝘪𝘷𝘢𝘮𝘦𝘯𝘵𝘦 𝘢 𝘴𝘤𝘰𝘱𝘪 𝘥𝘪 𝘳𝘪𝘤𝘦𝘳𝘤𝘢 (𝘙𝘜𝘖) 𝘦 𝘯𝘰𝘯 𝘱𝘦𝘳 𝘶𝘴𝘰 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤𝘰.
*𝘗𝘢𝘳𝘵𝘦𝘤𝘪𝘱𝘢𝘻𝘪𝘰𝘯𝘦 𝘴𝘶𝘱𝘱𝘰𝘳𝘵𝘢𝘵𝘢 𝘥𝘢 𝘉𝘪𝘰𝘤𝘢𝘳𝘵𝘪𝘴

💡 𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝗔𝗠𝗣 𝘄𝗼𝗿𝗸𝘀𝗵𝗼𝗽: 𝘍𝘢𝘴𝘵 𝘌𝘎𝘍𝘙 𝘛𝘦𝘴𝘵𝘪𝘯𝘨 𝘪𝘯 𝘊𝘺𝘵𝘰𝘱𝘢𝘵𝘩𝘰𝘭𝘰𝘨𝘺: 𝘈 𝘗𝘳𝘢𝘤𝘵𝘪𝘤𝘢𝘭 𝘐𝘮𝘱𝘭𝘦𝘮𝘦𝘯𝘵𝘢𝘵𝘪𝘰𝘯 𝘌𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦🗣️ Dr. Roberto Ruiz-Co...
20/10/2025

💡 𝗝𝗼𝗶𝗻 𝗼𝘂𝗿 𝗔𝗠𝗣 𝘄𝗼𝗿𝗸𝘀𝗵𝗼𝗽: 𝘍𝘢𝘴𝘵 𝘌𝘎𝘍𝘙 𝘛𝘦𝘴𝘵𝘪𝘯𝘨 𝘪𝘯 𝘊𝘺𝘵𝘰𝘱𝘢𝘵𝘩𝘰𝘭𝘰𝘨𝘺: 𝘈 𝘗𝘳𝘢𝘤𝘵𝘪𝘤𝘢𝘭 𝘐𝘮𝘱𝘭𝘦𝘮𝘦𝘯𝘵𝘢𝘵𝘪𝘰𝘯 𝘌𝘹𝘱𝘦𝘳𝘪𝘦𝘯𝘤𝘦
🗣️ Dr. Roberto Ruiz-Cordero (University of Miami)
🗓️ 12 November, 03:00 PM (EST)
📍 AMP 2025, Boston Convention & Exhibition Center, 156AB, level 1

Dr. Ruiz-Cordero will present results from the 𝗽𝗿𝗼𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲 𝗙𝗔𝗖𝗜𝗟𝗜𝗧𝗔𝗧𝗘 𝘀𝘁𝘂𝗱𝘆 exploring how Idylla™ can 𝗰𝗼𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁 𝗡𝗚𝗦 for EGFR testing in 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 tissue and 𝗰𝘆𝘁𝗼𝗹𝗼𝗴𝘆 𝘀𝗮𝗺𝗽𝗹𝗲𝘀 with 𝗺𝗶𝗻𝗶𝗺𝗮𝗹 𝘀𝗮𝗺𝗽𝗹𝗲 𝗶𝗻𝗽𝘂𝘁. Learn how fast molecular testing can help...
✅ Rescue Quantity Non Sufficient (QNS) NGS cases
✅ Reduce turnaround time
✅ Accelerate decisions
Join the workshop and gain practical insights into 𝗿𝗲𝗮𝗹-𝘄𝗼𝗿𝗹𝗱 𝗶𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 of EGFR testing in the cytopathology lab!

Be sure to also visit us at 𝗯𝗼𝗼𝘁𝗵 𝟰𝟮𝟭!
👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://lnkd.in/eVyaZ8qA
👉 𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗜𝗱𝘆𝗹𝗹𝗮™: https://lnkd.in/eRx8fbYs

We can’t wait to connect with you in Boston! 👋


Idylla™ EGFR Mutation Assay is for Research Use Only (RUO), not for use in diagnostic procedures.

15/10/2025

🚀 NOW AVAILABLE: 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐏𝐎𝐋𝐄-𝐏𝐎𝐋𝐃𝟏 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧 𝐀𝐬𝐬𝐚𝐲*
✅ Molecular classification of samples in ~ 95 min.
✅ Covers 99% of the known pathogenic & mutations
✅ Achieved 98.2% accuracy with 450+ endometrial cancer samples (Barault et al., 2024)
✅ Fit for use on small biopsies & directly from 1 FFPE tissue section
✅ No need for sample batching
✅ Straightforward results reporting

👉 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 https://www.biocartis.com/en/research/research-assays/idylla-pole-pold1-mutation-assay?utm_source=facebook&utm_medium=social&utm_campaign=1510_idylla-pole-pold1-mutation-assay

*For Research Use Only (RUO), not for use in diagnostic procedures.
Barault, L. et al. (2024). The Idylla™ POLE Mutation Assay, A New Tool For Direct Mutation Detection From FFPE Tissue. AMP 2024 Annual Meeting

Adres

Generaal De Wittelaan 11B
Mechelen
2800

Telefoon

+3215632600

Website

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Biocartis nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.

Contact De Praktijk

Stuur een bericht naar Biocartis:

Snelkoppelingen

Delen

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Type